Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 1999

View Archived Issues

SmithKline Beecham: Annual Report 1998/Q1 Report 1999

Sepracor: Q1 1999 highlights

Positive results achieved in Alexion's phase I/II study of 5G1.1 in RA

Alcon to continue Lu-Tex development

Synthetic antitumor agent derived from Et 743 shows promise following preliminary testing

OraVax: Q4 and year-end 1998 highlights

Another series of HDL-increasing compounds revealed by American Home Products

FDA approves Roche's lipase inhibitor for marketing

Vertex and Glaxo Wellcome begin shipping new anti-HIV compound

Lorus to acquire GeneSense

New phenylpropionic acid derivatives with excellent antidiabetic effects

Vasodilating benzamide and cinnamide derivatives from China

China Pharmaceutical University develops effective antiarrhythmic agents

Genta and NCI to collaborate on G-3139 clinical development

Anti-CD11/CD18 MAb not effective in phase II trial in exacerbations of MS

Series from Takeda with neuroprotective effects

U.S. study now under way using artificial liver device incorporating human cells

RiboGene issued two patents related to translation-targeted drug discovery

Cellegy initiates phase II testing of Anogesic in hemorrhoid surgery patients

Urethra-selective alpha1-agonists under development at Mitsui for urinary incontinence

European CPMP emits positive opinion on Zeffix for chronic HBV

New cyclic compounds designed at JT reduce only elevated blood glucose levels

Amgen: Q1 1999 highlights

Dual-action antiatherosclerotic agents in the Sankyo pipeline

BRAINS results presented at American Academy of Neurology meeting

Therapeutic Antibodies: year-end 1998 highlights

Pregabalin: first clinical experience in patients with refractory complex partial seizures

Muscarinic agonists fail to improve cognitive function in AD

Noncompetitive AMPA antagonist potentiates levodopa activity in primate PD model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...